When Arthur Conan Doyle wanted Sherlock Holmes to show off, he didn’t give him a bloody fingerprint or a dropped monocle. He gave him a dog that didn’t bark.

In Silver Blaze, the silence was the clue. The horse didn’t vanish because of a stranger—the stable dog knew the intruder. The absence of noise told Holmes everything.

That’s where we are with the newest trial of PCSK9s, a class of drug that dramatically lowers cholesterol levels.

At first glance, the study looks like a triumph of modern pharmacology. It’s a massive, multinational, double-blinded trial done at hundreds of sites in a dozen countries, enrolling nearly three thousand people. The paper trumpets spectacular reductions in LDL (half or more!) and a power analysis north of 99%. Reviewers nodded. Editors smiled. Headlines followed.

And yet: The dog never barked.

This drug class exists for one reason: to reduce cardiovascular events—heart attacks, strokes, and deaths. Cholesterol is not the goal, it is the surrogate. Human outcomes are the prize.

So where are they?

Nowhere in the paper. Nowhere in the abstract. Nowhere in the results. Nowhere, even, in the discussion of limitations. Not a single Kaplan–Meier curve. No exploratory table. Not even the typical cowardly offering—“CV outcomes will be reported separately.” Just, silence.

That is not an accident.

Holmes would first note the power analysis (a window to the soul of a study): The authors insist the trial was designed to have more than 99% power to prove the drug can lower LDL. But that is absurd on its face. Sniff test: failed. No regulator requires 99% power to prove a biomarker outcome. Eighty percent is standard. Ninety if you’re nervous. But as I’ve pointed out before, increasing power, by upping the number of participants, can be a cover story for ulterior motives.

And it’s pricey, to the tune of $50,000 or more per enrollment. Fiscally responsible companies don’t add study participants without a good reason. Which makes it notable that a standard power analysis for this trial suggests the researchers didn’t need to enroll three thousand people—they needed about twenty. Yup. Twenty. For the whole study. Both arms. The PCSK9 drugs drop cholesterol so powerfully that it takes very few participants to demonstrate it mathematically. Which means the company paid more than $140 million for seemingly extra, unnecessary enrollments.

So, what’s really happening here?

There is a clue that may at first seem small (Dr. Watson once said, "I am glad of all details, whether they seem to you relevant or not"): According to an online recruitment posting for this exact trial, the goal was not to lower cholesterol, but rather “to reduce major cardiovascular events, including cardiovascular death, heart attack and stroke, by lowering LDL-cholesterol.”

Ahaa.

There it is, in black and white. It takes thousands of subjects to find the tiny reductions in cardiac events that cholesterol lowering drugs can (under the best of conditions for the highest risk people) theoretically achieve. This explains the study’s size. Moreover, in a trial this expensive, CV events were not just possibly collected, they were inevitable. Logged. Coded. Reviewed. Sitting somewhere in a database.

Which brings us back to the dog.

Why not include the cardiovascular outcomes in the paper? Because they weren’t reduced. If CV outcomes had favored the drug, even weakly, they would have been mentioned or, more likely, headlined . But nary a mention. Not even, “Numerically fewer events, ” or “a favorable trend.” Journals allow that sort of nonsense. Regulators tolerate it. Marketing departments adore it.

Instead, nothing. That is not sloppiness, it’s subterfuge.

The brilliance of the design is that it allowed them to pivot. By claiming a primary endpoint of LDL reduction (a cakewalk for PCSK9s), and then massively inflating sample size, they could quietly chase their true goal, cardiovascular benefit—while still guaranteeing ‘success’.

Heads they win. Tails they don’t lose.

The drug succeeded at what was always easy: moving a lab value. But it failed at its secret raison d’être: helping humans.

Sherlock Holmes would have closed the file already. The most telling result of this enormous, costly, meticulously planned trial is not what it reported—but what it very carefully did not.

Get full access to Research Translation at researchtranslation.substack.com/subscribe